154 related articles for article (PubMed ID: 14513283)
1. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient.
Endo T; Nakao S; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Koike T
Ann Hematol; 2004 Feb; 83(2):114-6. PubMed ID: 14513283
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
3. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.
Nishio M; Endo T; Fujimoto K; Sato N; Sakai T; Obara M; Kumano K; Minauchi K; Koike T
Eur J Haematol; 2005 Dec; 75(6):527-9. PubMed ID: 16313268
[No Abstract] [Full Text] [Related]
4. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
5. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
Weinstock DM; Ambrossi GG; Brennan C; Kiehn TE; Jakubowski A
Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
[TBL] [Abstract][Full Text] [Related]
6. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
[TBL] [Abstract][Full Text] [Related]
7. Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient.
Brunner B; Kropshofer G; Ellemunter H; Brunner A; Mueller T; Margreiter R; Tzankov A
Pediatr Transplant; 2007 Aug; 11(5):547-51. PubMed ID: 17631026
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation.
Milpied N; Coste-Burel M; Accard F; Moreau A; Moreau P; Garand R; Harousseau JL
Bone Marrow Transplant; 1999 Mar; 23(6):629-30. PubMed ID: 10217196
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
13. Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant.
Zamkoff KW; Bergman S; Beaty MW; Buss DH; Pettenati MJ; Hurd DD
Bone Marrow Transplant; 2003 Feb; 31(3):219-22. PubMed ID: 12621485
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
15. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
[TBL] [Abstract][Full Text] [Related]
16. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection.
Uehara T; Nakaseko C; Hara S; Harima A; Ejiri M; Yokota A; Saito Y; Nishimura M
Am J Hematol; 2004 Aug; 76(4):368-72. PubMed ID: 15282671
[TBL] [Abstract][Full Text] [Related]
17. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
Raj K; Narayanan S; Augustson B; Ho A; Mehta P; Duncan N; Tauro S; Mahendra P; Craddock C; Mufti G
Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
[TBL] [Abstract][Full Text] [Related]
18. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy.
Cheng FW; Lee V; To KF; Chan KC; Shing MK; Li CK
Pediatr Blood Cancer; 2009 Dec; 53(7):1329-31. PubMed ID: 19591223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
